Cerevel Therapeutics Raises $350M Via Equity Issued At $25/Share

by Vandana Singh, Benzinga Editor

July 2, 2021 7:31 AM | 29 seconds read | Make a Comment

Cerevel Therapeutics Holdings Inc CERE has priced its previously announced underwritten public offering of 14 million shares at $25.00 per share, representing a discount of 7% from the last close price of $26.85 on Thursday.
The gross proceeds will be approximately $350 million.
Underwriters have an option to purchase up to an additional 2.1 million shares.
The offering will close by July 7.
Price Action: CERE shares are down 1.23% at $26.52 in the premarket session on the last check Friday.

Posted In: Biotech News Health Care Offerings General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.